(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 19.68% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Alvotech's revenue in 2026 is $562,043,000.On average, 7 Wall Street analysts forecast ALVO's revenue for 2026 to be $205,312,500,558, with the lowest ALVO revenue forecast at $183,240,150,331, and the highest ALVO revenue forecast at $221,010,683,175. On average, 7 Wall Street analysts forecast ALVO's revenue for 2027 to be $244,718,715,981, with the lowest ALVO revenue forecast at $205,877,497,785, and the highest ALVO revenue forecast at $297,182,298,255.
In 2028, ALVO is forecast to generate $301,312,084,614 in revenue, with the lowest revenue forecast at $254,517,203,799 and the highest revenue forecast at $360,224,751,256.